Trial Profile

A Multicentre, Randomised, Open-label, Phase 2 trial of mifamurtide combined with post-operative chemotherapy for newly diagnosed high risk osteosarcoma patients (metastatic osteosarcoma at diagnosis or localised disease with poor histological response)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mifamurtide (Primary) ; Cisplatin; Doxorubicin; Etoposide; Ifosfamide; Methotrexate
Indications Osteosarcoma
Focus Therapeutic Use
Acronyms SARCOME13

05 Jun 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Sep 2025.
08 Nov 2024 Planned primary completion date changed from 1 Oct 2024 to 1 Mar 2025.
01 Feb 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com